The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC.
 
Shubham Pant
Honoraria - 4D Pharma; 4D Pharma; 4D Pharma; 4D Pharma
Consulting or Advisory Role - TYME; TYME; TYME; TYME
Research Funding - ArQule (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Onco Response (Inst); Onco Response (Inst); Onco Response (Inst); Onco Response (Inst); RedHill Biopharma (Inst); RedHill Biopharma (Inst); RedHill Biopharma (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Rgenix (Inst); Rgenix (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst)
 
Sant P. Chawla
Honoraria - Amgen; Amgen; Amgen; Amgen; CytRx Corporation; CytRx Corporation; CytRx Corporation; CytRx Corporation; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Ignyta; Ignyta; Ignyta; Ignyta; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Roche; Roche; Roche; Roche; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; CytRx Corporation; CytRx Corporation; CytRx Corporation; CytRx Corporation; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Ignyta; Ignyta; Ignyta; Ignyta; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Roche; Roche; Roche; Roche; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; CytRx Corporation; CytRx Corporation; CytRx Corporation; CytRx Corporation; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Ignyta; Ignyta; Ignyta; Ignyta; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Roche; Roche; Roche; Roche; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Research Funding - Amgen; Amgen; Amgen; Amgen; CytRx Corporation; CytRx Corporation; CytRx Corporation; CytRx Corporation; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Ignyta; Ignyta; Ignyta; Ignyta; Immune Design; Immune Design; Immune Design; Immune Design; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Roche; Roche; Roche; Roche; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
 
Vincent Chung
Consulting or Advisory Role - Apeiron Biologics; Apeiron Biologics; Apeiron Biologics; Apeiron Biologics; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Ipsen; Ipsen; Ipsen; Ipsen; Perthera; Perthera; Perthera; Perthera; Westwood Bioscience; Westwood Bioscience; Westwood Bioscience; Westwood Bioscience
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Ipsen; Ipsen; Ipsen; Ipsen
Research Funding - Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
 
Giuseppe Del Priore
Employment - TYME; TYME; TYME; TYME
Leadership - TYME; TYME; TYME; TYME
Stock and Other Ownership Interests - TYME; TYME; TYME; TYME
Consulting or Advisory Role - TYME; TYME; TYME; TYME
 
Dae Won Kim
No Relationships to Disclose
 
Marcus Smith Noel
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Paul Eliezer Oberstein
Consulting or Advisory Role - BTG; BTG; BTG; BTG; Celgene; Celgene; Celgene; Celgene; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Purdue Pharma; Purdue Pharma; Purdue Pharma; Purdue Pharma; TYME; TYME; TYME; TYME
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck
 
Allyson J. Ocean
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Tyme; Tyme; Tyme; Tyme
Speakers' Bureau - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo
 
Philip Agop Philip
Honoraria - Amgen; Amgen; Amgen; Amgen; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Biologics; Biologics; Biologics; Biologics; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Caris MPI; Caris MPI; Caris MPI; Caris MPI; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Ipsen; Ipsen; Ipsen; Ipsen; Lexi Pharma; Lexi Pharma; Lexi Pharma; Lexi Pharma; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Sanofi; Sanofi; Sanofi; Sanofi; SynCoreBio; SynCoreBio; SynCoreBio; SynCoreBio; TriSalus Life Sciences; TriSalus Life Sciences; TriSalus Life Sciences; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Merrimack; Merrimack; Merrimack; Merrimack; novartis; novartis; novartis; novartis; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; TriSalus Life Sciences; TriSalus Life Sciences; TriSalus Life Sciences; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); boston biomedical (Inst); boston biomedical (Inst); boston biomedical (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); halozyme (Inst); halozyme (Inst); halozyme (Inst); halozyme (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); Momenta Pharmaceuticals (Inst); Momenta Pharmaceuticals (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); novartis (Inst); novartis (Inst); novartis (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Regeneron (Inst); Regeneron (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst); TYME (Inst); tyme (Inst); tyme (Inst); TYME (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie; celgene; celgene; celgene; celgene; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals
 
Vincent J. Picozzi
Stock and Other Ownership Interests - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Halozyme; Halozyme; Halozyme; Halozyme
Research Funding - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Celgene; Celgene; Celgene; Celgene; FibroGen; FibroGen; FibroGen; FibroGen; Immunomedics; Immunomedics; Immunomedics; Immunomedics; OncoMed; OncoMed; OncoMed; OncoMed
 
Diane M Simeone
No Relationships to Disclose
 
Andrea Wang-Gillam
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Jacobio; Jacobio; Jacobio; Jacobio; Merrimack; Merrimack; Merrimack; Merrimack; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); BioMed Valley Discoveries (Inst); BioMed Valley Discoveries (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CTI (Inst); CTI (Inst); CTI (Inst); CTI (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); pfizer (Inst); pfizer (Inst); pfizer (Inst); pfizer (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Precision Therapeutics (Inst); Precision Therapeutics (Inst); Precision Therapeutics (Inst); Precision Therapeutics (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst); Xcovery (Inst); Xcovery (Inst); Xcovery (Inst); Xcovery (Inst)